Morgan Stanley’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-83,019
| Closed | -$108K | – | 8167 |
|
|
2025
Q2 | $108K | Sell |
83,019
-30,679
| -27% | -$36.9K | ﹤0.01% | 6099 |
|
|
2025
Q1 | $158K | Sell |
113,698
-16,071
| -12% | -$35.2K | ﹤0.01% | 5831 |
|
|
2024
Q4 | $297K | Sell |
129,769
-40,642
| -24% | -$108K | ﹤0.01% | 5636 |
|
|
2024
Q3 | $464K | Buy |
170,411
+62,227
| +58% | +$152K | ﹤0.01% | 5438 |
|
|
2024
Q2 | $253K | Buy |
108,184
+44,418
| +70% | +$142K | ﹤0.01% | 5576 |
|
|
2024
Q1 | $299K | Sell |
63,766
-109,832
| -63% | -$570K | ﹤0.01% | 5561 |
|
|
2023
Q4 | $847K | Buy |
173,598
+140,094
| +418% | +$582K | ﹤0.01% | 5377 |
|
|
2023
Q3 | $156K | Sell |
33,504
-3,716
| -10% | -$21.4K | ﹤0.01% | 5693 |
|
|
2023
Q2 | $275K | Buy |
37,220
+7,370
| +25% | +$49.2K | ﹤0.01% | 5502 |
|
|
2023
Q1 | $244K | Sell |
29,850
-13,350
| -31% | -$139K | ﹤0.01% | 5619 |
|
|
2022
Q4 | $413K | Sell |
43,200
-2,063
| -5% | -$25.4K | ﹤0.01% | 5334 |
|
|
2022
Q3 | $532K | Sell |
45,263
-5,433
| -11% | -$71.6K | ﹤0.01% | 5238 |
|
|
2022
Q2 | $651K | Buy |
50,696
+10,375
| +26% | +$108K | ﹤0.01% | 5278 |
|
|
2022
Q1 | $444K | Buy |
40,321
+11,786
| +41% | +$137K | ﹤0.01% | 5480 |
|
|
2021
Q4 | $436K | Sell |
28,535
-94,616
| -77% | -$1.24M | ﹤0.01% | 5626 |
|
|
2021
Q3 | $1.72M | Buy |
123,151
+12,649
| +11% | +$211K | ﹤0.01% | 4686 |
|
|
2021
Q2 | $2.14M | Buy |
+110,502
| New | +$2.28M | ﹤0.01% | 4579 |
|
Morgan Stanley's AKYA Position: Q3 2025 in Review
Morgan Stanley sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 83,019 shares — an estimated $108K sold.
Morgan Stanley first reported a position in AKYA in Q2 2021 and held it in 17 quarters. The position peaked at $2.14M in Q2 2021. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- Morgan Stanley reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- Morgan Stanley sold 83,019 Akoya BioSciences shares in Q3 2025, an estimated $108K.
- Morgan Stanley first reported a position in Akoya BioSciences in Q2 2021 and held it in 17 quarters.
- Morgan Stanley's Akoya BioSciences position peaked at $2.14M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.